Trial Profile
A phase II trial of VELCADE [bortezomib] in patients with metastatic or locally recurrent nasopharyngeal carcinoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 19 May 2020
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 14 May 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 10 Oct 2006 New trial record.